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Juvenile myelomonocytic leukemia (JMML) is a commonly fatal myeloid leukemia 
occurring in very young children bearing germline or somatic mutations in genes within the 
RAS-ERK signaling pathway including NF1, CBL, KRAS, NRAS, and PTPN11 (1). 
Leukemia relapse following allogeneic stem cell transplant is uncharacteristically high at 
40–50% for JMML patients, and findings from the recently published manuscript by Dong 
et al. (2) provide some clues that might account for this high relapse rate. The authors found 
that Nestin-Cre-mediated knock-in of Ptpn11E76K/+, resulting in mutant Shp2 expression in 
bone marrow (BM) mesenchymal stem/progenitor and neural cells, induced activation of 
otherwise normal hematopoietic stem and progenitor cells to differentiate into myeloid cells. 
The resulting leukemia recapitulated the features of JMML, with splenomegaly, 
myelocytosis, and increased myelopoiesis in the BM. While Mx1-Cre- and LysM-Cre-
mediated knock-in of Ptpn11E76K/+ have previously been shown to cause a JMML-like 
myeloproliferative neoplasm (MPN) in mice (3), this is the first study demonstrating that 
BM niche-restricted expression of Ptpn11E76K/+ is capable of producing disease. The 
elegance of the present study lies in the use of five tissue-specific Cre promoters which 
identified mesenchymal stem/progenitor cells and osteoprogenitors as the critical mutated 
BM microenvironment cell types with the capacity to promote myeloid disease, ruling out 
differentiated osteoblasts and endothelial cells.
Relevant to human disease and hematopoietic stem cell (HSC) transplantation as the 
standard treatment for JMML, the authors found that lethally irradiated Ptpn11E76K/+Nestin-
Cre+ mice transplanted with wild-type (WT) BM cells develop a donor-derived MPN, 
demonstrating the mutant BM microenvironment’s pathogenic effect on transplanted normal 
cells. A potential mechanism accounting for the development of the donor WT cell-derived 
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MPN is the overproduction of the CC chemokine, CCL3, resulting in recruitment of 
inflammatory monocytes to the HSC niche, production of inflammatory cytokines such as 
IL-1β, and displacement of HSCs from their normal quiescence-promoting niches. These 
findings imply an explanation for the poor engraftment and relapse seen in JMML patients 
after HSC transplantation (4,5). The commonly observed resurgence of the JMML leukemic 
clone following stem cell transplantation may be due to the inability of the donor normal 
HSCs to engraft and remain in a quiescent state in the aberrant BM microenvironment, 
permitting outgrowth of residual leukemic cells and patient relapse. The findings from Dong 
et al. that the abnormal microenvironment is antagonistic to HSC self-renewal and 
quiescence further imply that HSCs and progenitors are more likely to mobilize into the 
peripheral organs, which is a common cause of mortality for JMML patients (6).
In the reciprocal experiment, the authors found that transplantation of BM cells from 
Ptpn11E76K/+Nestin-Cre+ mice with chronic phase MPN did not produce disease in recipient 
WT mice, however, transplantation of BM cells from moribund Ptpn11E76K/+Nestin-Cre+ 
mice produced donor-derived disease in the WT recipients. These findings indicate that over 
time, the aberrant microenvironment induced the HSCs to acquire alterations, which 
conferred increased HSC self-renewal. Notably, treatment of Ptpn11Osx1-Cre+ mice with 
chronic phase MPN with CCL3 receptor antagonists decreased and even reversed MPN 
development, suggesting that once the abnormal niche signal is suppressed by the 
antagonists, the HSCs are able to resume their normal function. Therefore, the timing of 
intervention is potentially crucial, and perhaps prophylactic anti-inflammatory drugs 
targeting the BM niche may be beneficial for JMML patients post-transplant.
The findings that an abnormal microenvironment by itself can induce JMML give 
researchers the rationale to further explore the role of oncogenes specifically in the stromal 
cells, with their expression under the control of Nestin-Cre. Although there are already high 
throughput methods to screen drugs in vitro (7), the authors have validated 
Ptpn11E76K/+Nestin-Cre+ mice as an in vivo model for testing drugs that target altered 
microenvironments. The importance of verifying results in vivo is highlighted in this study, 
as the authors found no hyperactivation of HSCs when co-cultured with Ptpn11E76K/+ 
stromal cells or with exogenous CCL3 in vitro, yet the HSCs were hyperactivated by the in 
vivo mutant microenvironment. In the future, the exploration of putative interactions 
between the microenvironment and hematopoietic cells, their mutual influence on each 
other, and resultant contribution to leukemogenesis will be of great interest. Further work 
into the underlying mechanisms, such as chemokine receptor downstream signaling, which 
includes phospholipase C and activation of the MAP kinase pathway (8), will also be highly 
rewarding to find other targets for inhibition.
It is important to keep in mind that while the authors’ findings are clearly applicable to the 
development/progression of germline mutant PTPN11-induced syndromic JMML (due to 
the described stromal expression of Ptpn11E76K/+), these findings are also relevant to 
somatic mutant PTPN11-induced sporadic JMML. Since some components of the BM 
microenvironment are hematopoietic-derived, such as the megakaryocyte niche (9), a clean 
separation between the hematopoietic cell-derived and stromal cell-derived BM 
microenvironment does not exist. Thus, the BM microenvironments of JMML patients 
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bearing somatic as well as germline mutations are likely similarly abnormal, and the 
authors’ findings in mice of poorer engraftment in hyperinflammatory niches are applicable 
to patients with sporadic and syndromic JMML alike. Given the harsh nature of allogeneic 
stem cell transplant as well as the unfortunate high relapse rate in JMML, further 
investigation of microenvironment-targeting therapies in both syndromic and sporadic 
JMML is merited.
Acknowledgements
Funding: This work was supported by R21 CA202296 (RJ Chan) and F30 CA210518 (L Deng).
References
1. de Vries AC, Zwaan CM, van den Heuvel-Eibrink MM. Molecular basis of juvenile 
myelomonocytic leukemia. Haematologica 2010;95:179–82. [PubMed: 20139388] 
2. Dong L, Yu WM, Zheng H, et al. Leukaemogenic effects of Ptpn11 activating mutations in the stem 
cell microenvironment. Nature 2016;539:304–8. [PubMed: 27783593] 
3. Xu D, Liu X, Yu WM, et al. Non-lineage/stage-restricted effects of a gain-of-function mutation in 
tyrosine phosphatase Ptpn11 (Shp2) on malignant transformation of hematopoietic cells. J Exp Med 
2011;208:1977–88. [PubMed: 21930766] 
4. Bergstraesser E, Hasle H, Rogge T, et al. Non-hematopoietic stem cell transplantation treatment of 
juvenile myelomonocytic leukemia: a retrospective analysis and definition of response criteria. 
Pediatr Blood Cancer 2007;49:629–33. [PubMed: 16991133] 
5. Locatelli F, Nöllke P, Zecca M, et al. Hematopoietic stem cell transplantation (HSCT) in children 
with juvenile myelomonocytic leukemia (JMML): results of the EWOGMDS/EBMT trial. Blood 
2005;105:410–9. [PubMed: 15353481] 
6. Germing U, Kündgen A, Gattermann N. Risk assessment in chronic myelomonocytic leukemia 
(CMML). Leuk Lymphoma 2004;45:1311–8. [PubMed: 15359628] 
7. Hartwell KA, Miller PG, Mukherjee S, et al. Niche-based screening identifies small-molecule 
inhibitors of leukemia stem cells. Nat Chem Biol 2013;9:840–8. [PubMed: 24161946] 
8. Curnock AP, Logan MK, Ward SG. Chemokine signalling: pivoting around multiple 
phosphoinositide 3-kinases. Immunology 2002;105:125–36. [PubMed: 11872087] 
9. Heazlewood SY, Neaves RJ, Williams B, et al. Megakaryocytes co-localise with hemopoietic stem 
cells and release cytokines that up-regulate stem cell proliferation. Stem Cell Res 2013;11:782–92. 
[PubMed: 23792434] 
Deng and Chan Page 3
Transl Cancer Res. Author manuscript; available in PMC 2019 October 24.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
